Page 125 - ITPS-7-2
P. 125

INNOSC Theranostics and
            Pharmacological Sciences                                          PI3K-α inhibitors for cancer immunotherapy



            value of 0.8825, held a stronger correlation with the model   protein-ligand complex.  On the other hand, hydrogen
                                                                                  82
            than other PLS factors, even as PLS factor 3 ranked next.   bond acceptor interactions illustrate how ligands accept
            However, the rank which the degree of correlation is   electrons from a protein donor, stabilize the complex, and
            depicted in the following trend:                   enhance ligand recognition within the protein, in which
                                                                                                     83
              Pearson−r: PLS factor 4 ⟹ PLS factor 3 ⟹ PLS factor 2   the hydrogen bond paring influences shifts in pKa values
            ⟹ PLS factor 1                                     of interacting groups and also affects charge distribution
                                                               and electrostatic potential. 84
              The table can be used to compare different models with
            different numbers of factors and select the best one based on   In conjunction with  Table 3, the visualization of
            the given statistical criteria. However, a good QSAR model   the interactive contributions of the different Gaussian
            should not only have a high R  value but also have high   descriptors in the context of PLS factor 3 under study is
                                     2
            predictive power, robustness, interpretability, applicability,   graphically presented in Figure 10.
            etc. It is logical to choose a model that has high R , Q , and   3.6. Rational design of a new ligand
                                                     2]
                                                   2
            Pearson-r, and a low RMSE and p-value, while avoiding
                                                 2
            overfitting (indicated by a large gap between R  and R  CV   3.6.1. Skeletal modifications
                                                      2
            or a high R Scr) and instability (indicated by a low stability).   Medicinal chemistry continues to be impacted by
                    2
            It is inferred from Table 2 that PLS factors 4 and 3 were   innovative  in silico  methods, especially at the drug
            the best performers among other PLS factors. To compare,   discovery stage using QSAR models. In this study, we
            PLS factor 4 performed better than PLS factor 3 in terms   attempted to design a new compound with enhanced
            of fit, significance, accuracy, reliability, and correlation,   binding affinity and specificity by enacting the desired
            but worse in terms of variation, prediction, generalization,   chemical transformations on a reference ligand in a concise
            and stability. Based on these critical criteria, PLS factor 3   and chemospecific fashion. The concept of “molecular
            was considered the optimal PLS factor, which offered the   editing” involves building onto, modifying, or pruning
            safest approach that accounted for model performance and   molecules atom by atom, utilizing transformations that are
            quality.                                           adequately mild and selective for application in the later
              Table 3 displays the percentage contribution of   stages of drug synthesis and sequencing. 85
            different Gaussian descriptors in the QSAR model for each   The skeletal editing of the top-ranked hit compound
            number of PLS factors used in the model. The Gaussian   (Candidate 1, in Table 1), which was obtained from the
            descriptors encode the mean and covariance information   robust virtual screening-molecular docking workflow,
            of local features in a  graphical object.  In  Table 3,  PLS   involved some heterocyclic modifications that were in
                                           81
            factor 3 comprised 27.3% steric, 10.5% electrostatic, 19.4%   conformation with the congeneric series of molecules
            hydrophobic, 25.8% hydrogen bond acceptor, and 17%   used in docking. The molecular modification between the
            hydrogen bond donor descriptors. These values indicate   reference compound and the resulting T85 is illustrated
            the contribution of each Gaussian descriptor to PLS factor   in  Figure  11. The skeletal editing of the reference hit
            3 in analyzing the relationship between the predictor   compound was associated with molecular modifications
            variables and the response variable in the regression   in the heterocycles of its oxazole and the oxetane-pyridine
            model. The result suggests that most of the binding energy   sub-cores, with fluorination and bipyridine formation
            predominantly emanated from steric (27%) and hydrogen   dispatched, respectively. However, the fluorination
            bond acceptor (25.8%) interactions. Steric and hydrogen   involved  the  replacement of  the  2-methyl  group  on the
            bond acceptor interactions influence protein-ligand   oxazole ring by a fluorine atom, and the pyridine ring was
            binding affinity and specificity. Steric interactions depict   fused with another pyridine ring at the 3-position.  The
            the shape complementarity and spatial fit of the ligand, as   resulting putative ligand, referred to as T85, holds promise
            well as influence the entropy of the binding process of the   as the next synthetic hit compound.

            Table 3. Molecular field fraction analysis

            # PLS        Gaussian        Gaussian          Gaussian        Gaussian hydrogen   Gaussian hydrogen
            factors      steric (%)   electrostatic (%)  hydrophobic (%)   bond acceptor (%)    bond donor (%)
            1            0.428119        0.056828          0.172533           0.217674             0.124847
            2            0.315070        0.093522          0.197463           0.237846             0.156099
            3            0.273183        0.105146          0.194088           0.257736             0.169848
            4            0.312171        0.093195          0.190332           0.260085             0.144218


            Volume 7 Issue 2 (2024)                         15                               doi: 10.36922/itps.2340
   120   121   122   123   124   125   126   127   128   129   130